Sustainability Report

This sustainability report refers to financial year 2025 and applies to the parent company Immunovia AB (publ) (org. no. 556730-4299) and all entities consolidated in Immunovia's consolidated accounts for the same period. These are stated in Note 22 of the Annual Report 2025. This report has been prepared without Immunovia having any legally mandatory requirement to do so. The report is not based on any specific sustainability standard but on the regulations of the Swedish Annual Accounts Act.

The Board of Directors and CEO have also approved the sustainability report when signing off the annual report and the consolidated accounts.

Approach

To guide the sustainability work Immunovia has implemented a set of company policies.
With the decision in July 2023 to withdraw the IMMray™ PanCan-d test from the market and to restructure operations, the scope of Immunovia's operations and number of employees have declined substantially and thereby also the scope of the sustainability report. Against this backdrop, the sustainability report from 2024 onwards is significantly shorter compared with previous years.

Focus Areas

The sustainability work within Immunovia relates to three focus areas: Public Welfare, Sustainable Products and Sustainable Workplace.

SOCIAL WELFARE

Immunovia's ambition is to create value by being able to detect pancreatic cancer considerably earlier and more precisely than what is currently possible.

Mission

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.

Immunovia is focused on the commercialization of simple blood-based testing to detect proteins and antibodies that indicate if a high-risk individual has developed pancreatic cancer.

Social Value Chain

The prerequisite for sustainable business development and success lies in creating long-term relationships with our employees, customers and suppliers.

Collaboration with partners is key to Immunovia's success. Working with world-renowned research centers and clinics provides the necessary access to patient samples and data, as well as crucial clinical expertise. Ongoing close relationships with key opinion leaders and patient advocacy organizations is also essential, as they provide important insights, knowledge and ability to influence change.

These partnerships and others have, by way of example, enabled Immunovia to acquire the samples needed to develop its next-generation test. These relationships are also important to the cost-efficient, rapid study of the PancreaSure test because these key opinion leaders are able to incorporate Immunovia's test into larger clinical studies they are conducting.

Anti-Corruption
Solid business ethics are essential, and guidelines are regulated in Immunovia's Code of Conduct. The company has pronounced zero tolerance to corruption and does not accept bribes or unfair anti-competitive measures.

No cases of corruption or any other unethical business conduct were detected during the year.

SUSTAINABLE PRODUCTS AND PROCESSES
Immunovia has during 2025 developed and validated its next-generation blood test to detect pancreatic cancer in high-risk individuals. In doing so, the company has switched to using the commercially available ELISA platform for the new test to enable faster and more cost-effective production of the test compared to the previous proprietary IMMray™ platform.

During the remainder of 2026, Immunovia will continue to conduct additional clinical studies of the PancreaSure test to further characterize the accuracy of the test as well as its utility in screening high-risk individuals.

Commercialization of the PancreaSure test in the US
The Company has chosen to first commercialize its next-generation test in the United States. The appeal and priority of the U.S. market is primarily driven by four factors. First, the potential market is very large. Second, the regulatory framework allowed the Company to launch the test as a lab-developed test, which is a shorter regulatory pathway to launch. Third, prices for diagnostic tests are generally higher in the United States than in Europe or Asia. Finally, Immunovia has developed relationships with numerous U.S. experts in pancreatic cancer, which facilitates the commercial introduction of PancreaSure.

To commercialize the test, Immunovia expects to partner with a large diagnostics company that has an existing sales force. Partnering to commercialize the test will reduce the company's costs and will require less investment than building a large sales team of its own. It should also accelerate adoption by leveraging the existing relationships between the commercialization partner's sales reps and their clinicians.

Reimbursement of the next-generation test
Reimbursement from public and private sector insurers in the US market is crucial for market uptake of new tests. Immunovia conducted studies in 2025 and will conduct additional clinical studies in 2026 and beyond to secure the clinical data required to secure reimbursement from US payers.

Key risks

Risks	Mitigation
Risk related to availability of financing	The Company is dependent on access to external financing to support its operations and strategic initiatives. There is a risk that such financing may not be available on acceptable terms, or at all, which could adversely affect the Company's financial position and ability to execute its business plan. The Company actively monitors its liquidity position and evaluates potential financing alternatives on an ongoing basis.
The company's tests will not be covered by national guidelines for treatment or by cost compensation programs.	The Company has a multi-faceted program to secure reimbursement. These efforts include extensive clinical studies, development of support from advocacy groups, and collaboration with key opinion leaders.

SUSTAINABLE WORKPLACE

Our Employees

End of 2025 the number of employees was 13 (9).

Immunovia's employees are an absolute prerequisite for the company to be successful, especially considering the very lean organization.

Immunovia operates in a global environment with employees from a variety of backgrounds. Equality and diversity are about a fair distribution of power, influence and resources and are key factors that determine success of the company.

Risks	Mitigation
Key people leaving the organization	The Company's CEO and management team continually look for opportunities to help employees grow and develop. Employees are empowered and trusted to do their best work and are supported in these endeavors by their managers, the CEO and the Board of Directors.

Summary

The 2025 sustainability report for Immunovia gives a brief summary of the company's focus on sustainability and outlines how the Company is building and nurturing a sustainable organization.